UK Markets closed

MorphoSys AG (MOR.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
27.06-0.25 (-0.92%)
At close: 05:35PM CET
Full screen
Previous close27.31
Open26.99
Bid26.96 x 1500
Ask26.99 x 8800
Day's range26.17 - 27.10
52-week range25.21 - 100.30
Volume195,526
Avg. volume352,813
Market cap923.855M
Beta (5Y monthly)0.79
PE ratio (TTM)N/A
EPS (TTM)-4.54
Earnings date14 Mar 2022 - 18 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est65.28
  • EQS Group

    MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report

    DGAP-News: MorphoSys AG / Key word(s): Miscellaneous24.01.2022 / 22:01 The issuer is solely responsible for the content of this announcement.MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index ReportMorphoSys AG (FSE: MOR; NASDAQ: MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report, ranking number one in Germany and number two among European healthcare com

  • EQS Group

    MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference

    DGAP-News: MorphoSys AG / Key word(s): Conference10.01.2022 / 08:00 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 10, 2022MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare ConferenceMorphoSys AG (FSE: MOR; NASDAQ: MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday January 12, 2022 at 5:15 p.m. EST.Li

  • EQS Group

    MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance

    DGAP-News: MorphoSys AG / Key word(s): Forecast07.01.2022 / 07:59 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 07, 2022MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance- Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million (€ 66.9 million)- Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 millionMorphoSys AG (FSE: MOR; NASDAQ: MOR) today rep